

# Selective Killing of Adriamycin-Resistant ( $G_2$ Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel

Zoya N. Demidenko,<sup>1</sup> Dorota Halicka,<sup>1</sup> Jan Kunicki,<sup>1</sup> James A. McCubrey,<sup>2</sup> Zbigniew Darzynkiewicz,<sup>1</sup> and Mikhail V. Blagosklonny<sup>1</sup>

<sup>1</sup>Brander Cancer Research Institute, New York Medical College, Valhalla, New York and <sup>2</sup>Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, North Carolina

## Abstract

**Chemotherapy of cancer is limited by toxicity to normal cells. Drug resistance further limits the therapy. Here, we investigated selective killing of drug-resistant cancer cells by antagonistic drug combinations, which can spare (because of drug antagonism) normal cells. We used paired cell lines that are resistant to Adriamycin due to either expression of MRP1 or lack of  $G_2$  checkpoints. The goal was to selectively kill Adriamycin-resistant cancer cells with Docetaxel (Taxotere), while protecting parental (Adriamycin-sensitive) cells, using cytostatic concentrations of Adriamycin. Taxotere kills cells in mitosis. Therefore, by arresting parental cells in  $G_2$ , 20 to 40 ng/mL of Adriamycin prevented cell death caused by Taxotere. Also, Adriamycin prevented the effects of Taxotere in normal human lymphocytes. In contrast, Taxotere selectively killed MRP1-expressing leukemia cells, which did not undergo  $G_2$  arrest in the presence of Adriamycin. Also, in the presence of Adriamycin, HCT116-p21<sup>-/-</sup> cancer cells with a defective  $G_2$  checkpoint entered mitosis and were selectively killed by Taxotere. Finally, 20 ng/mL of Adriamycin protected normal FDC-P1 hematopoietic cells from Taxotere. Whereas parental cells were protected by Adriamycin, the mitogen-activated protein/extracellular signal-regulated kinase inhibitor PD90598 potentiated the cytotoxic effect of Taxotere selectively in Raf-1-transformed FDC-P1 leukemia cells. We propose a therapeutic strategy to prevent normal cells from entering mitosis while increasing apoptosis selectively in mitotic cancer cells.** (Cancer Res 2005; 65(10): 4401-7)

## Introduction

Microtubules represent one of the best drug targets identified to date (1–5). Docetaxel (Taxotere), a microtubule-stabilizing taxane, is widely used in the therapy of breast, ovarian, prostate, lung, head and neck, gastric, bladder and other cancers (6–9). Yet, microtubules are universal cellular structures that are necessary for all normal cells. As a consequence, all microtubule-active agents cause dose-limiting side effects (10, 11).

Microtubule dynamics is much faster during mitosis (M) than during interphase ( $G_1$ , S,  $G_2$ ) of the cell cycle (2). At low concentrations, which do not cause polymerization of tubulin, taxanes inhibit mitotic progression (2, 12). Numerous studies indicate that inhibition of mitotic progression and mitotic arrest correlate with the cytotoxicity of microtubule-active drugs (13–21). When arrested in  $G_1$  and/or  $G_2$ , cells are resistant to microtubule-active

drugs (22–27). DNA-damaging agents cause  $G_1$  and/or  $G_2$  arrest (28). In particular, low concentrations of Adriamycin can cause  $G_2$  arrest without apoptosis. Therefore, low concentrations of Adriamycin can protect cells from microtubule-active drugs (24, 26). But how can we arrest normal cells in  $G_2$  without arresting cancer cells? First, cancer cells may have defective  $G_2$  checkpoints (29–31). Following DNA damage, such cancer cells continue to proliferate and enter mitosis (28). Second, cancer cells may acquire drug resistance, for instance, due to expression of MRP1 (32). Adriamycin is a substrate of MRP1, whereas Taxotere is not (33, 34). In the presence of low concentrations of Adriamycin, in theory, Taxotere could kill MRP1-expressing cells selectively. Here we investigated these scenarios. We showed that following pretreatment with low concentrations of Adriamycin, Taxotere selectively killed MRP1-expressing and  $G_2$  checkpoint-deficient cells. We also determined a protective window: namely, concentrations of Adriamycin that arrest cell cycle without causing cell death. Finally, the mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor PD90859 potentiated the effects of Taxotere in Raf-1-transformed cells arrested in mitosis, whereas normal FDC-P1 hematopoietic cells were protected by Adriamycin.

## Materials and Methods

**Cell lines.** HCT116 and cells lacking p21<sup>-/-</sup> (defective  $G_1$  and  $G_2$ ), Bax<sup>-/-</sup> and Securin<sup>-/-</sup>, were obtained from Bert Vogelstein (John Hopkins University). HL60 and HL/Adriamycin were described previously (35, 36). Hematopoietic FDC-P1 and Raf-1-transfected (FDC/Raf-1) cells were described previously (37, 38).

**Lymphocytes.** Human peripheral blood lymphocytes were isolated from healthy volunteers by venipuncture. Cells were maintained in culture and treated with 10 mg/mL phytohemagglutinin, as previously described (39).

**Reagents.** Docetaxel (Taxotere) was obtained from Aventis Pharmaceuticals, Inc. (Bridgewater, NJ). Adriamycin (Doxorubicin) and PD90859 were obtained from Sigma (St. Louis, MO).

**Immunoblot analysis.** Cells were lysed and soluble proteins were harvested in TNES buffer [50 mmol/L Tris-HCl (pH 7.5), 100 mmol/L NaCl, 2 mmol/L EDTA, 1 mmol/L sodium orthovanadate, and 1% (v/v) NP40] containing protease inhibitors (20 mg/mL aprotinin, 20 mg/mL leupeptin, and 1 mmol/L phenylmethylsulfonyl fluoride). Proteins were resolved with either 12% SDS-PAGE (for Bcl-2) or with NuPAGE 4% to 12% Bis-Tris gel with MOPS running buffer (NOVEX, San Diego, CA) according to the manufacturer's instructions. Immunoblotting was done with mouse monoclonal anti-p21 and anti-p53 (Oncogene Research, Calbiochem, La Jolla, CA), mouse monoclonal anti-human tubulin and actin (Sigma). Immunoblots were developed using a horseradish peroxidase-conjugated secondary antibody (Bio-Rad, Richmond, CA) and a chemiluminescence detection kit (Dupont NEN, Boston, MA).

**3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.** Floating cells (20,000; HL60, HL/Adriamycin, FDC-P1, FDC/Raf-1, lymphocytes) or 5,000 adherent cells (HCT116 cells and their clones) were plated in 96-well flat-bottomed plates and then exposed to tested agents.

**Requests for reprints:** Mikhail V. Blagosklonny, Cancer Center, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208. Fax: (518) 614-6305; E-mail: blagosklonny@hotmail.com.

©2005 American Association for Cancer Research.

After 3 or 4 days, 20  $\mu\text{L}$  of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) was added to each well for 4 hours. After removal of the medium, 170  $\mu\text{L}$  of DMSO was added to each well to dissolve the formazan crystals. The absorbance at 540 nm was determined using a Biokinetics plate reader as previously described (40). SD were determined in triplicate.

**Number of dead and live cells.** Cells were plated in 24-well plates in 1 mL of medium, or in 96-well plates in 0.2 mL, and were treated with drugs. Cells were incubated with trypan blue and the number of blue (dead) cells and transparent (live) cells were counted by a hemocytometer.

**Flow cytometry.** Cells were harvested, washed with PBS, and resuspended in 75% ethanol in PBS and kept at 4°C for at least 30 minutes. Cells were resuspended and incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide (Sigma), 1 mmol/L EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension was then analyzed on a Becton Dickinson FACScan. DNA content frequency histograms were measured using a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA). To calculate the percentage of cells in respective phases of the cell cycle, the DNA content frequency histograms were deconvoluted using the MultiCycle software (Phoenix Flow Systems, San Diego, CA).


**In situ DNA strand break labeling (terminal nucleotidyl transferase-mediated nick end labeling assay).** Cells were rinsed with PBS, fixed in 1% methanol-free formaldehyde for 15 minutes at room temperature and stored in 70% ethanol at -20°C for at least 1 hour. The cells were then rinsed twice with PBS for 5 minutes. DNA strand break labeling was done using the APO-BRDU kit provided by Phoenix Flow Systems. After washing with PBS, cells were stained with propidium iodide (5  $\mu\text{g}/\text{mL}$ ) and dissolved in PBS containing RNase A for 20 minutes. Cellular fluorescence was measured using a FACScan flow cytometer (Becton Dickinson).

**Mitotic index and apoptotic nuclei.** Cells were incubated with drugs for the indicated times. Cells washed with PBS, pelleted onto glass slides in a cytocentrifuge, fixed with 90% ethanol/10% glacial acetic acid. Nuclei were stained with 1  $\mu\text{g}/\text{mL}$  of 4',6-diamidino-2-phenylindole (DAPI, Molecular Probes, Inc., Eugene, OR) in PBS and inspected under UV microscope (Nikon Microphot) as previously described (41, 42).

## Results

**Premittotic arrest protects HL60 cells from Taxotere.** First, we compared the cytotoxicity of Taxotere in exponentially growing HL60 cells and nondividing HL60 cells that were arrested in  $G_1$  by high cell density (2,000,000 cells/mL). At concentrations >10 nmol/L, Taxotere was cytotoxic in proliferating HL60 cells. In contrast, quiescent HL60 cells were resistant to Taxotere-induced cytotoxicity (Fig. 1A), consistent with the notion that Taxotere kills dividing cells only. Next, we investigated whether pharmacologic arrest could also protect HL60 cells from Taxotere. Previously, we have found that 50 ng/mL Adriamycin causes  $G_2$  arrest in HL60 cells, thus preventing them from entering mitosis (41). As shown in Fig. 1A, pretreatment HL60 cells with 50 ng/mL Adriamycin abrogated cytotoxic effects of Taxotere. Because cell death and inhibition of proliferation cannot always be distinguished by the MTT cytotoxicity assay, we also measured the number of dead and live cells by trypan blue exclusion. By day 2, Taxotere killed all HL60 cells (Fig. 1B). Importantly, pretreatment with Adriamycin abrogated cell death caused by Taxotere (Fig. 1B).

**Selective killing MRP-expressing leukemia cells.** By pumping drugs out, Pgp and MRP provide very high levels of drug resistance (32). For example, HL60/MRP cells, a multidrug-resistant cell line that express MRP1, grow in the presence of 500 to 1,000 ng/mL Adriamycin (35, 43). In contrast, HL/MRP are sensitive to Taxotere (Fig. 2A), because Taxotere is not a substrate of MRP1. Because HL/MRP cells proliferate in the presence of Adriamycin, Taxotere will kill such cells. When cells were pretreated with Adriamycin, HL/




**Figure 1.** Doxorubicin prevents the cytotoxic effects of Taxotere. **A**, cytotoxicity of Taxotere in proliferating and quiescent HL60 cells. (Quiescent) HL60 cells were growing until quiescence at high cell density HL60; (regular) exponentially growing HL60 cells (from 250,000 to 1,500,000/mL); (regular + Adriamycin) exponentially growing cells HL60 cells were treated with 40 ng/mL Adriamycin. Then cells at quiescent, regular, and regular + Adriamycin conditions were treated with Taxotere and MTT assay was done after 48 hours. **B**, pretreatment with 60 nmol/L Taxotere, 40 ng/mL Adriamycin, Adriamycin + Taxotere, or left untreated. Adriamycin was added 16 hours before Taxotere. When Taxotere was added, the medium was changed to remove Adriamycin. After 48 hours, the number of dead and live cells was measured by trypan blue exclusion.

MRP cells continue to grow. Taxotere efficiently kills HL/MRP (Fig. 2B). In contrast, Adriamycin protected HL60 cells. Thus, pretreatment with Adriamycin allowed Taxotere to kill MRP-expressing cells selectively (Fig. 2B).

In controls, both HL60 and HL/MRP cells were distributed in all phases of the cell cycle (Figs. 3 and 4). As expected, in both HL60 and HL/MRP cells Taxotere caused  $G_2$ -M arrest (by flow cytometry) that was actually mitotic arrest by DAPI staining (Figs. 3 and 4). Taxotere-treated cells underwent apoptosis as evidenced by DNA strand breaks [terminal nucleotidyl transferase-mediated nick end labeling (TUNEL) assay]. In the presence of Adriamycin, HL60 cells accumulated in the  $G_2$  phase but not in mitosis (no mitotic nuclei by DAPI staining; Fig. 3, Adriamycin) and no apoptosis was detected by TUNEL. Most importantly, pretreatment with Adriamycin prevented mitotic arrest and apoptosis caused by Taxotere (Taxotere versus Adriamycin + Taxotere). Essentially, when treated with either Adriamycin alone or Adriamycin followed by Taxotere, HL60 cells were arrested in  $G_2$  and did not undergo apoptosis (Fig. 3). In brief, Adriamycin + Taxotere = Adriamycin.

Taxotere induced mitotic arrest and apoptosis in MRP-expressing HL60 cells (Fig. 4). In contrast, Adriamycin had no effect in these cells (Fig. 4). There was no difference between control and Adriamycin-treated HL/MRP cells (control versus Adriamycin). Therefore, the  $G_2$ -M peak was purely mitotic in both Taxotere-treated and Adriamycin + Taxotere-treated cells (Fig. 4). In agreement, Adriamycin did not prevent apoptosis caused by Taxotere (Fig. 4). Essentially, when treated with either Taxotere alone or Taxotere following Adriamycin, MRP-expressing cells were arrested in mitosis and underwent apoptosis. In brief, Adriamycin + Taxotere = Taxotere.

**Protective and discriminating windows.** Thus, 50 ng/mL of Adriamycin protected HL60 cells from Taxotere. How wide is this protective window of Adriamycin concentrations? We treated



**Figure 2.** Pretreatment with Adriamycin protects parental but not MRP-expressing HL60 cells. *A*, cells were treated with Taxotere. MTT assay was done after 48 hours as described in Materials and Methods. *B*, cells were pretreated with 40 ng/mL Adriamycin. After 16 hours, cells were treated with Taxotere. MTT assay was done after 48 hours as described in Materials and Methods.


HL60 and HL/MRP cells with increasing concentrations of Adriamycin (Fig. 5). After 16 hours, we changed the medium and added 60 nmol/L Taxotere. Taxotere alone (Adriamycin = 0) was toxic to both HL60 and HL/MRP cells. At cytostatic concentrations (20-80 ng/mL), Adriamycin protected parental HL60 cells. This protection was maximal at 40 ng/mL. At higher concentrations, Adriamycin was cytotoxic to HL60 cells. Therefore, a protective window was about 4-fold (20-80 ng/mL). At these concentrations, there was no protection of HL/MRP cells. Approximately 100-fold higher concentrations of Adriamycin (3,000 ng/mL) affected HL/MRP cells. Simply, at high concentrations of Adriamycin, MRP cannot pump the drug out completely. Therefore, a discrimination window between HL60 and HL/MRP was about 100-fold (Fig. 5).


**Prevention of Taxotere-induced mitotic arrest in human normal lymphocytes.** Next, we wished to establish whether 50 ng/mL Adriamycin could prevent the effects of Taxotere in primary normal cells such as lymphocytes. Phytohemagglutinin-stimulated lymphocytes were either treated with 50 ng/mL Adriamycin or left untreated. After 8 hours, cells were either treated with 60 nmol/L Taxotere or left untreated for an additional 16 hours (Fig. 6). As expected, Taxotere arrested lymphocytes in mitosis (Fig. 6). This was followed by apoptosis. In contrast, no mitotic or apoptotic cells were detected in Adriamycin-pretreated lymphocytes, following treatment with Taxotere. This result confirmed that low concentrations of Adriamycin could arrest normal human lymphocytes without killing them and thus prevent the effects of Taxotere.

**Selective killing of cancer cells lacking G<sub>2</sub> checkpoint.** Low concentrations of Adriamycin activate G<sub>2</sub> checkpoint. Loss of cell cycle checkpoints is common in human cancer. Here we compared p21<sup>-/-</sup> cells lacking G<sub>2</sub> checkpoint (28) with parental HCT116 cells having a proficient G<sub>2</sub> checkpoint. In parental HCT116 cells, Adriamycin induced p21 (Fig. 7A). As expected, there was no induction of p21 in p21<sup>-/-</sup> cells (Fig. 7A). Taxotere alone was cytotoxic in both cell lines (Fig. 7B). Pretreatment with Adriamycin abrogated Taxotere-induced cytotoxicity in parental cells but not in cells lacking p21 (Fig. 7B).

In HCT116 cells, Adriamycin induced G<sub>1</sub> and G<sub>2</sub> arrest (Fig. 8). In p21<sup>-/-</sup> cells, Adriamycin caused accumulation of tetraploid (G<sub>2</sub>) cells (Fig. 8), which actually entered mitosis. Therefore, in p21<sup>-/-</sup> cells, pretreatment with Adriamycin did not prevent the cytotoxic effects of Taxotere. In the presence of Adriamycin, Taxotere arrested p21<sup>-/-</sup> cells in mitosis (Fig. 9). Furthermore, a sub-G<sub>1</sub> apoptotic peak was evident in p21<sup>-/-</sup> cells treated with Adriamycin + Taxotere (Fig. 8A). In parental HCT116 cells that were arrested in G<sub>2</sub> by Adriamycin (Fig. 8), Taxotere did not cause mitotic arrest (Fig. 9). We conclude that, whereas parental HCT116 cells were protected by Adriamycin, p21<sup>-/-</sup> cells lacking G<sub>2</sub> checkpoint were selectively killed by Taxotere.

**Figure 3.** Cell cycle distribution and apoptosis: protection of parental HL60 cells. HL60 cells were incubated with 60 nmol/L Taxotere, 40 ng/mL Adriamycin, with 40 ng/mL Adriamycin (12 hours) followed by 60 nmol/L Taxotere, or left untreated. Flow cytometry and TUNEL (apoptotic) assay was done as described in Materials and Methods after 16 hours.







**Figure 4.** Cell cycle distribution and apoptosis: selective killing of MRP-expressing cells. (HL/MRP cells) cells were incubated with 60 nmol/L Taxotere, 40 ng/mL Adriamycin, with 40 ng/mL Adriamycin (12 hours) followed by 60 nmol/L Taxotere, or left untreated. Flow cytometry and TUNEL (apoptotic) assay was done as described in Materials and Methods after 16 hours.

**Selective effects on FDC-P1 and FDC/Raf-1 cells.** Major side effects of Taxotere are due to its cytotoxicity to hematopoietic cells. Therefore, we investigated the protection of cytokine-dependent FDC-P1 hematopoietic cells from Taxotere. Low concentrations of Adriamycin (10-20 ng/mL) diminished the cytotoxicity of Taxotere (Fig. 10A). FDC/Raf-1 are cytokine-independent malignant cells (38). Raf-1 kinase inhibits apoptosis and renders cells resistant to cell cycle arrest. Therefore, FDC/Raf-1 cells were resistant to both Adriamycin and Taxotere (Fig. 10A). Taxotere was only marginally cytotoxic to these cells both in the absence (Fig. 10A, 0 ng/mL Adriamycin) and in the presence of Adriamycin (Fig. 10A, 10-200 ng/mL Adriamycin). We attempted to sensitize FDC/Raf-1 cells to Taxotere while


protecting FDC-P1 cells with low concentrations of doxorubicin. First, 20 ng/mL Adriamycin protected parental cells from cell death caused by Taxotere (Fig. 10B). To potentiate the cytotoxicity of Taxotere in FDC/Raf-1 cells, we used PD98059,



**Figure 5.** Protective window (PW) and discriminating window (DW). HL60 and HL/MRP1 cells were pretreated with indicated concentrations of Adriamycin (X-axis). After 12 hours, cells were treated with Taxotere and MTT assay was done as described in Materials and Methods.




**Figure 6.** Adriamycin prevented Taxotere-induced mitotic arrest in lymphocytes. Human blood lymphocytes were stimulated with phytohemagglutinin for 2 days. Then, lymphocytes were either treated with 50 ng/mL Adriamycin or left untreated. After 8 hours, cells were further treated with 60 nmol/L Taxotere or left untreated for an additional 16 hours.




**Figure 7.** Adriamycin-induced p21 and Taxotere-induced cytotoxicity. **A**, Adriamycin induced p21 in parental HCT116 cells. Cells were treated with 50 ng/mL Adriamycin, then p21 and actin were measured after 16 hours. **B**, selective cytotoxicity of Adriamycin + Taxotere in p21<sup>-/-</sup> cells. Cells were treated with 50 ng/mL Adriamycin and 60 nmol/L Taxotere and MTT assay was done after 2 days, as described in Materials and Methods.

an inhibitor of MEK, which is a downstream target of Raf-1. It has been shown that inhibition of MEK renders cells sensitive to apoptosis caused by microtubule-active drugs (37, 44–47). It has been shown that cells treated with paclitaxel followed by PD98059 exhibited a significant increase in apoptosis, whereas pretreatment of cells with PD98059 reduced cell lethality (48). This suggests that PD98059 is preferentially cytotoxic to mitosis-arrested cells but not G<sub>2</sub>-arrested cells. We confirmed this prediction. The addition of PD98059 after Adriamycin and Taxotere resulted in significant killing of FDC/Raf-1 cells, whereas parental cells were protected (Fig. 10B, Adriamycin + Taxotere + PD).




**Figure 8.** Effects of Adriamycin and Taxotere on cell cycle distribution in parental and p21<sup>-/-</sup>-deficient HCT116 cells. HCT116 cells (parental) and HCT116-p21<sup>-/-</sup> (p21<sup>-/-</sup>) were pretreated, if indicated, with 50 ng/mL Adriamycin for 12 hours, and then treated with 60 nmol/L Taxotere. After 16 hours, flow cytometry was done.



**Figure 9.** The combination Adriamycin + paclitaxel causes mitotic arrest selectively in p21<sup>-/-</sup> cells. Parental HCT116 cells and p21<sup>-/-</sup> cells were pretreated with 50 ng/mL Adriamycin for 12 hours, and then treated with 60 nmol/L Taxotere for 16 hours. DAPI nuclei staining reveals mitotic patterns.

**Discussion**

The goal of cancer therapy is to kill cancer cells, without devastating side effects. Taxanes, at low concentrations, inhibit mitotic microtubules leading to mitotic arrest and, at higher concentrations, cause tubulin polymerization. Accordingly, there are two types of side effects due to (a) mitotic arrest in dividing cells (“mitotic” side effects) and (b) tubulin polymerization in nondividing neurons (neuropathy). As could be predicted, neuropathy occurs with higher doses of taxanes (10, 49, 50). For therapeutic effects, taxanes do not need to be used at doses and schedules that cause neurologic effects (50).



**Figure 10.** Preferential killing of Raf-1-expressing FDC/Raf-1 cells while protecting parental FDC-P1. **A**, protective concentrations of Adriamycin. FDC-P1 and FDC/Raf-1 cells were pretreated with indicated concentrations (X-axis) of Adriamycin for 8 hours. At 0 ng/mL Adriamycin (X-axis), cells were left untreated. After 8 hours, the medium was changed and both Adriamycin-treated and untreated cells were treated with 60 nmol/L Taxotere. MTT assay was done after 64 hours. **B**, PD98059 sensitizes Taxotere-treated FDC/Raf-1 to cell death. When indicated, cells were pretreated with 20 ng/mL Adriamycin for 8 hours (ADR). Then, 60 nmol/L Taxotere was added (+TX). After 6 hours, cells were post-treated with 20 μmol/L PD98059. After 2 days, dead cells were counted with trypan blue. Cell numbers in thousands per well ± m.

Mitotic side effects are caused by damage of proliferating bone marrow cells (manifested as myelosuppression), epithelial cells in intestine, stomach, mouth (as diarrhea, nausea, and mucosites), hair follicles (as hair loss). Mitotic side effects may seem inevitable because therapeutic effects also depend on mitotic arrest (in cancer cells). Technically, mitotic side effects are markers of therapeutic doses. To prevent mitotic side effects, we suggest to selectively arrest normal cells in G<sub>2</sub>. Then, Taxotere is expected to cause mitotic arrest in cancer cells selectively. Here, we showed that low concentrations of Adriamycin arrested Adriamycin-sensitive cells in G<sub>2</sub>, thus protecting them from Taxotere. In contrast, cancer cells with defective G<sub>2</sub> checkpoints and MRP1-expressing cells were selectively killed by Taxotere.

Whereas normal cells are arrested in G<sub>2</sub>, it is important to ensure that cancer cells undergo cell death following Taxotere-induced mitotic arrest because Raf-1-transformed FDC-P1 cells are resistant to Taxotere-mediated cytotoxicity. Here we present the proof of principle of how to selectively increase the cytotoxic effects of Taxotere in such cells. For example, inhibitors of MEK increase apoptosis in cancer cells that are arrested in mitosis (37, 44–48). We showed that PD90859 sensitized FDC/Raf-1 cells to cell death caused by Taxotere. But to avoid sensitization of normal cells, they should first be prevented from entering mitosis. Because low concentrations of Adriamycin can arrest cells with normal G<sub>2</sub> checkpoint, without arresting cancer cells, we can selectively attack cancer cells arrested in mitosis. The goal is (a) to prevent normal cells from entering mitosis by causing G<sub>2</sub> arrest and (b) to prevent cancer cells from exiting mitosis by inducing apoptosis. It is important to emphasize that because low doses of Adriamycin will protect cells, they will not select for drug resistance. If anything, cancer cells that are sensitive to Adriamycin may be selected. Probably, due to tumor heterogeneity, some cancer cells with normal cell cycle checkpoints might be protected by Adriamycin.

Yet, most deranged and drug-resistant cancer cells will not be protected by Adriamycin and thus will be eliminated.

Animal studies may be useful for proofs of principle and to validate new protective agents. For example, Mdm-2 antagonists, which induce p53 without DNA damage, are of particular interest (51, 52). Yet, in the case of Adriamycin, animal studies may be neither particularly informative nor absolutely necessary. The crucial goal is protection of normal host cells, not merely killing of human tumor xenografts. Normal mouse and human cells differ in their sensitivities to DNA-damaging agents. Also, side effects in humans and mice are different (e.g., hair loss in humans). In addition, it may be difficult to translate *in vitro* concentrations to animal doses and then to patient doses. On the other hand, Adriamycin is a widely used anticancer drug with well-known dose-toxicity relationships. Thus, all information is available to design a clinical trial. For protection of normal cells, Adriamycin should be used just under its toxic doses. In patients with Adriamycin-resistant tumors, these doses are expected to decrease the side effects of Taxotere without protection of the tumor. The end point of such a clinical trial is a decrease of side effects caused by Taxotere. This is easily detectable. If reduction of side effects will be achieved, this will have far-reaching consequences in cancer therapy, allowing one to add synergistic agents to potentiate Taxotere selectively in cancer cells.

## Acknowledgments

Received 12/10/2004; revised 1/25/2005; accepted 2/8/2005.

**Grant support:** Preclinical concept research grant from Aventis Corp. to M.V. Blagosklonny and a National Cancer Institute grant R01CA098195 to J.A. McCubrey.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

## References

- Horwitz SB. Personal recollections on the early development of taxol. *J Nat Prod* 2004;67:136–8.
- Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. *Curr Opin Cell Biol* 1998;10:123–30.
- Giannakakou P, Sackett D, Fojo T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. *J Natl Cancer Inst* 2000;92:182–3.
- Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. *Curr Cancer Drug Targets* 2003; 3:193–203.
- Hait WN, Rubin E, Goodin S. Tubulin-targeting agents. *Cancer Chemother Biol Response Modif* 2003;21:41–67.
- Blagosklonny MV. Analysis of FDA-approved anticancer drugs reveals the future of cancer therapy. *Cell Cycle* 2004;3:1035–42.
- Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. *Annu Rev Med* 1997;48:353–74.
- Hong WK. The current status of docetaxel in solid tumors. *An M.D. Anderson Cancer Center Review. Oncology (Huntingt)* 2002;16:59–15.
- Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. *Oncologist* 2004;9:S24–32.
- Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. *J Natl Cancer Inst Monogr* 1993;15:107–15.
- Rowinsky EK. On pushing the outer edge of the outer edge of paclitaxel's dosing envelope. *Clin Cancer Res* 1999;5:481–6.
- Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. *Nat Rev Cancer* 2004;4:253–65.
- Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. *Proc Natl Acad Sci U S A* 1993;90:9552–6.
- Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G<sub>1</sub> phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. *Cancer Res* 1994; 54:4355–61.
- Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. *Mol Medicine* 1995;1:506–26.
- Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G<sub>2</sub>-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. *Cancer Res* 1997;57:2388–93.
- Ling Y-H, Consoli U, Tornos C, Andreeff M, Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. *Int J Cancer* 1998;75:925–32.
- Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality. *Int J Cancer* 1999;83:151–6.
- Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. *Cancer Res* 1998; 58:3620–6.
- Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. *Oncogene* 2003;22:9075–86.
- Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. *Cancer Res* 2004;64: 5760–6.
- Grem JL, Nguyen D, Monahan BP, Kao V, Geoffroy FJ. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. *Biochem Pharmacol* 1999;58:477–86.
- Li W, Fan J, Banerjee D, Bertino JR. Overexpression of p21(waf1) decreases G<sub>2</sub>-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. *Mol Pharmacol* 1999;55: 1088–93.
- Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. *J Clin Invest* 2000;105:533–9.
- Blagosklonny MV, Bishop PC, Robey R, Fojo T, Bates S. Loss of cell cycle control allows selective microtubule drug-induced Bcl-2 phosphorylation and cytotoxicity in highly autonomous cancer cells. *Cancer Res* 2000;60: 3425–8.
- Zeng S, Chen YZ, Fu L, Johnson KR, Fan W. *In vitro* evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. *Clin Cancer Res* 2000; 6:3766–73.
- Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G<sub>1</sub>/G<sub>2</sub> cell cycle arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. *Oncogene* 2001;20: 3806–13.
- Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G<sub>2</sub> arrest after DNA damage. *Science* 1998;282:1497–501.

29. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. *Cancer Cell* 2002;2:103-12.
30. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004;10:789-99.
31. Dash BC, El-Deiry WS. Cell cycle checkpoint control mechanisms that can be disrupted in cancer. *Methods Mol Biol* 2004;280:99-161.
32. Fojo T, Bates S. Strategies for reversing drug resistance. *Oncogene* 2003;22:7512-23.
33. van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. *Oncol Rep* 1998;5:249-55.
34. Alvarez M, Robey R, Sandor V, et al. Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles. *Mol Pharmacol* 1998;54:802-14.
35. Blagosklonny MV, Alvarez M, Fojo A, Neckers LM. Bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. *Leuk Res* 1996;20:101-7.
36. Blagosklonny MV. Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. *Leukemia* 1999;13:2031-5.
37. Hoyle PE, Moye PW, Steelman LS, et al. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. *Leukemia* 2000;14:642-56.
38. Shelton JG, Blalock WL, White ER, Steelman LS, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. *Cell Cycle* 2004;3:372-9.
39. Du L, Smolewski P, Bedner E, Traganos F, Darzynkiewicz Z. Selective protection of mitogenically stimulated human lymphocytes but not leukemic cells from cytosine arabinoside-induced apoptosis by LY294002, a phosphoinositol-3 kinase inhibitor. *Int J Oncol* 2001;19:811-9.
40. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. *Cancer Res* 2004;64:3653-60.
41. Blagosklonny MV. Sequential activation and inactivation of G<sub>2</sub> checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. *Oncogene* 2002;21:6249-54.
42. Blagosklonny MV, Darzynkiewicz Z, Halicka HD, et al. Paclitaxel induces primary and postmitotic G<sub>1</sub> arrest in human arterial smooth muscle cells. *Cell Cycle* 2004;3:1050-6.
43. Krishnamachary N, Ma L, Zheng L, Safa AR, Center MS. Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. *Oncol Res* 1994;6:119-27.
44. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. *J Biol Chem* 2000;275:38953-6.
45. Navolanic PM, Lee JT, McCubrey JA. Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway. *Cancer Biol Ther* 2003;2:677-8.
46. McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. *Mol Pharmacol* 2001;60:290-301.
47. Zelivianski S, Spellman M, Kellerman M, et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. *Int J Cancer* 2003;107:478-85.
48. Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase/ mitogen-activated protein kinase pathway. *Mol Pharmacol* 2001;60:143-54.
49. Postma TJ, Vermorken JB, Liefing AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. *Ann Oncol* 1995;6:489-94.
50. Rowinsky EK. The taxanes: dosing and scheduling considerations. *Oncology* 1997;11:7-19.
51. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. *Cell Cycle* 2004;3:419-21.
52. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. *Cancer Res* 2005;65:1918-24.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Selective Killing of Adriamycin-Resistant ( $G_2$ Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel

Zoya N. Demidenko, Dorota Halicka, Jan Kunicki, et al.

*Cancer Res* 2005;65:4401-4407.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/65/10/4401>

**Cited articles** This article cites 50 articles, 16 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/65/10/4401.full#ref-list-1>

**Citing articles** This article has been cited by 3 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/65/10/4401.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/65/10/4401>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.